Perspective Therapeutics Announces That The First Patients Were Dosed In Two New Cohorts Of Phase 1/2a Studies In Neuroendocrine Tumors And Solid Tumors, Respectively

Benzinga Newsdesk www.benzinga.com Neutral 67.5%

Neg 0% Neu 67.5% Pos 0%

Comments

No comments yet. Be the first!